Zensights Q2 2026 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we are pleased to share an update on merger and acquisition activity to help our clients...
Zensights Q1 2026 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we are pleased to share an update on merger and acquisition activity to help our clients understand...
View Full Whitepaper Presidential Executive Order Banning DTC Advertising What If the Saber Rattling Came to Fruition? By ZENSIGHTS December 2025 Executive Summary For nearly four decades, direct-to-consumer (DTC) pharmaceutical advertising has been a defining...
Zensights Q4 2025 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we’re pleased to share an update on merger and acquisition activity to help our clients...
View Full Whitepaper Alternative Funding Programs: Enabling Access or Eroding Value? The Pharma Dilemma By ZENSIGHTS Subject Matter Expert Eric Brandon December 2025 Executive Summary The rising cost of specialty medications has become one of the most pressing...
Zensights Q3 2025 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we’re pleased to share an update on merger and acquisition activity to help our clients...